Entos Pharmaceuticals awarded $4 million in grant funding from CIRM to support its congenital generalized lipodystrophy program.
Amount Raised
$4 Million
Round Type
Seed
EdmontonBiotechnologyHealth CareGeneticsTherapeuticsDescription
Entos Pharmaceuticals has secured a $4M grant from the California Institute for Regenerative Medicine to assist in the development of ENTLEP001, a genetic medicine for treating congenital generalized lipodystrophy. The funding will facilitate the completion of IND-enabling activities for the therapy, which shows promise in preclinical studies.
Who to call at Entos Pharmaceuticals, and when
A new round usually means Entos Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Entos Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Entos Pharmaceuticals, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Entos Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Entos Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.